CLE-HM04E-100μg / 询价
CLE-HM04E-500μg / 询价
CLE-HM04E-500μgx2 / 询价
- 客服电话
- 技术支持
Human CLEC4M/CD299 Protein
Recombinant Human CLEC4M/CD299 Protein is expressed from HEK293 without tag.It contains Gln71-Glu399 [Accession | Q9H2X3-1].
The protein has a predicted MW of 37.72 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CLEC4M on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CLEC4M is greater than 95% as determined by SEC-HPLC.
CLEC4M, also known as DC-SIGNR, L-SIGN or CD209L, is a Ca2+-dependent C-type lectin. CLEC4M and its homologue DC-SIGN are encoded by the closely related lectin gene cluster on chromosome 19p13.3. higher expression of CLEC4M is associated with poor clinical prognosis in lung cancer patients and enhances the resistance of NSCLC cells to cisplatin. Inhibition of CLEC4M expression significantly increased cisplatin sensitivity, suggesting potential clinical significance for targeting CLEC4M in overcoming cisplatin resistance.
CLEC4M; CD299; DC-SIGNR; DC-SIGN2; L-SIGN; CD209L; CD209L1
Tan LM, Li X, Qiu CF, Zhu T, Hu CP, Yin JY, Zhang W, Zhou HH, Liu ZQ. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J Cancer. 2019 Oct 19;10(25):6374-6383. doi: 10.7150/jca.30139. PMID: 31772670; PMCID: PMC6856750.
